Author/Editor		Tomažič, Janez
Title		Sepsa po presaditvi organov
Translated title		Sepsis after organ transplantation
Type		članek
Source		In: Baklan Z, Reberšek-Gorišek J, Kotnik-Kervokljan B, editors. Zbornik predavanj in praktikum Bedjaničev simpozij z mednarodno udeležbo o temi Sepsa in septični šok; 2003 maj 31-31; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2003
Volume		str. 119-29
Language		slo
Abstract		Unrecognized bacteremia in the organ donor does not have a negative clinical impact on the outcome of organ transplant recipients. Immune system of septic recipient after organ transplantation is severely compromised and unable to eradicate pathogens. Severe sepsis in recipients of organ transplants is associated with a high mortality, due to underlying comorbidities and immunosuppression. It represents highly complex challenges in management. Current clinical advances in the treatment of sepsis include tight control and regulation of blood glucose, early goal-directed therapy to treat the cellular oxygen defecit and therapy with drotrecogin alpha (human activated protein C). Conventional treatment of sepsis in patients after organ transplantation has nof specifically attempted to treat the underlying inflammatory or procoagulant responses that contribute to the development of multisystem organ failure. Drotrecogin alpha (activated) has been shown to be safe and effective adjuvant in the treatment of severe sepsis, but there is no experience in recipients of organ transplants. Case reports of fulminant septic shock and multiple organ failure after organ transplantations and treated with drotrecogin alpha (activated) are presented. Controlled clinical trials are warranted to further investigate the safety and efficacy of drotrecogin alfa (activated) in this patient population.
Descriptors		SEPSIS ORGAN TRANSPLANTATION SHOCK, SEPTIC OPPORTUNISTIC INFECTIONS INSULIN PROTEIN C